Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 14/20 | 0.37 |
| ▸ | PRKCA | P17252 | 6/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770787 | 0.89 | PDE10A (0.35) | MAPK1 | |
| SCHEMBL23770621 | 0.89 | PDE10A (0.35) | MAPK1 | |
| SCHEMBL23770748 | 0.89 | RORC (0.33) | PTPN11PRKCAPRKCQGSK3B | |
| SCHEMBL23770649 | 0.84 | PIM1 (0.34) | PTPN11PRKCQ | |
| SCHEMBL23770480 | 0.84 | GRIN2B (0.33) | — | |
| SCHEMBL23770712 | 0.83 | NPC1 (0.33) | — | |
| SCHEMBL23770464 | 0.83 | LMNA (0.34) | — | |
| SCHEMBL23770448 | 0.81 | CKS1B (0.40) | — | |
| SCHEMBL23770629 | 0.80 | PTPN1 (0.32) | — | |
| SCHEMBL19925767 | 0.80 | PTPN11 (0.38) | PTPN11PRKCAPRKCQMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |